Advertisement
[adinserter block="11" template="Global Header" check="exceptions" ignore="page-type"]
Home »

Stereotactic Ablative Radiotherapy Safe for Unresectable NSCLC With ILD

Apr 29, 2024

REFERENCES & ADDITIONAL READING

Palma D, et al. Stereotactic radiation therapy in early non-small cell lung cancer and interstitial lung disease: a nonrandomized clinical trial. JAMA Oncol. Published online March 7, 2024. doi:10.1001/jamaoncol.2023.7269

Weiner A, et al. Prospective data on stereotactic ablative radiotherapy provides guidance in an unusual clinical scenario. JAMA Oncol. Published online March 7, 2024. doi:10.1001/jamaoncol.2023.7039

ABOUT THE EXPERTS

  • Alexander Chin, MD, MBA
    Clinical Assistant Professor
    Department of Radiation Oncology
    Stanford School of Medicine

     

    Alexander Chin, MD, MBA, has indicated to Physician’s Weekly that he has a financial relationship with TibaRay, Inc.

     

    Ticiana Leal, MD
    Associate Professor
    Department of Hematology and Medical Oncology
    Emory University School of Medicine

     

    Ticiana Leal, MD, has indicated to Physician’s Weekly that she has financial relationships with AbbVie, Amgen, AstraZeneca, BMS, Catalyst, Eisai, Genentech/Roche, Janssen, Jazz, Merck, Novartis, Novacure, OncoC4, Pfizer, Sanofi/Regeneron, and Takeda.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
[adinserter block="22" template="Article Pages" check="exceptions" ignore="page-type"]
Advertisement
ad
ad
[adinserter block="23" template="Article Pages" check="exceptions" ignore="page-type"]
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement
[adinserter block="4" template="Article Pages" check="exceptions" ignore="page-type"]